Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

Acta Pharmacol Sin. 2020 Sep;41(9):1141-1149. doi: 10.1038/s41401-020-0485-4. Epub 2020 Aug 3.

Abstract

Coronavirus disease 2019 is a newly emerging infectious disease currently spreading across the world. It is caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The spike (S) protein of SARS-CoV-2, which plays a key role in the receptor recognition and cell membrane fusion process, is composed of two subunits, S1 and S2. The S1 subunit contains a receptor-binding domain that recognizes and binds to the host receptor angiotensin-converting enzyme 2, while the S2 subunit mediates viral cell membrane fusion by forming a six-helical bundle via the two-heptad repeat domain. In this review, we highlight recent research advance in the structure, function and development of antivirus drugs targeting the S protein.

Keywords: SARS-CoV-2 virus; antibodies; antivirus drugs; fusion inhibitors; host proteases inhibitors; spike protein.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / pharmacology*
  • Betacoronavirus* / drug effects
  • Betacoronavirus* / physiology
  • COVID-19
  • Coronavirus Infections* / drug therapy
  • Coronavirus Infections* / virology
  • Drug Discovery / methods
  • Humans
  • Pandemics*
  • Pneumonia, Viral* / drug therapy
  • Pneumonia, Viral* / virology
  • SARS-CoV-2
  • Spike Glycoprotein, Coronavirus / physiology*
  • Virus Internalization / drug effects*

Substances

  • Antiviral Agents
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2